Stabilization of Factor VIII in Plasma by the von Willebrand Factor

STUDIES ON POSTTRANSFUSION AND DISSOCIATED FACTOR VIII AND IN PATIENTS WITH VON WILLEBRAND’S DISEASE

HARVEY J. WEISS, IRA I. SUSSMAN, and LEON W. HOYER

From the Department of Medicine (Division of Hematology), The Roosevelt Hospital and Columbia University College of Physicians and Surgeons, New York, 10019, the Division of Hematology, Queens General Hospital-Long Island Jewish Medical Center, Jamaica, New York 11432, and the University of Connecticut School of Medicine, Farmington, Connecticut 06032

ABSTRACT In normal plasma, the ratio of the procoagulant activity of factor VIII (VIII_{AHF}) to that of the von Willebrand factor activity (ristocetin cofactor, VIII_{vWF}) or factor VIII antigen (VIII_{AGN}) is ~1, but ratios >1 (e.g., VIII_{AHF} > VIII_{vWF} or VIII_{AGN}) may be observed in some patients with von Willebrand’s disease and in the “late” posttransfusion plasmas of patients with this disorder. The lability of VIII_{AHF} was studied by incubating plasma, diluted 1:10 in imidazole buffer pH 7.1, for 6 h at 37°C. With normal plasmas, 77±12% (SD) of the original VIII_{AHF} activity remained after incubation. VIII_{AHF} was labile (e.g., 35–55% residual activity) in the “late” posttransfusion plasmas (VIII_{AHF} > VIII_{vWF}) of a patient with von Willebrand’s disease, but not in the “early” posttransfusion plasmas (VIII_{AHF} ~ VIII_{vWF}). VIII_{AHF} was also labile in the (base-line) plasmas of three patients with von Willebrand’s disease in whom the ratios of VIII_{AHF} to VIII_{vWF} were 4.4 to 8.1, but not in the plasmas of four other patients in whom the ratio was ~1. The electrophoretic mobility of factor VIII antigen was increased in two of the three patients with labile VIII_{AHF}. In both of these patients, and in the late posttransfusion plasmas, labile VIII_{AHF} activity could be stabilized by the addition of purified von Willebrand factor (lacking VIII_{AHF} activity) or by hemophilic plasma, but not by plasmas of patients with severe von Willebrand’s disease. Thus, VIII_{vWF} may serve to stabilize VIII_{AHF} and this might explain the posttransfusion findings in von Willebrand’s disease.

INTRODUCTION

Recent studies suggest that factor VIII is a macromolecule, or macromolecular complex, having two biologic functions. One activity of factor VIII corrects the clotting defect in hemophilia (antihemophilic factor, AHF, or VIII_{AHF} activity); another corrects defects of platelet function in von Willebrand’s disease (1, 2). The levels of these two activities in plasma can be quantified by biologic assays in which the activity of pooled normal plasma is designated as 100% activity. In normal plasmas, the ratio of these two activities is generally close to 1.0 (3, 4). However, under various circumstances, the levels of these activities can be “dissociated.” One type of dissociation is often seen in patients with von Willebrand’s disease who have been transfused with normal plasma or cryoprecipitate; characteristically, the level of VIII_{AHF} may remain increased when that of the von Willebrand factor (VIII_{vWF}), and factor VIII antigen (VIII_{AGN}), has returned to low values (5, 6). Injection of epinephrine into some patients with this disorder may also result in a disproportionate increase in VIII_{AHF} levels (7). Another type of dissociation has been observed in some patients with von Willebrand’s disease who show levels of VIII_{AHF} that are relatively higher than those for VIII_{vWF} (3, 4, 8–10) or both VIII_{vWF} and VIII_{AGN}

1 Abbreviations used in this paper: C/S, cryoprecipitate supernate ratio of VIII_{AHF}; STI, soybean trypsin inhibitor; VIII_{AGN}, factor VIII antigen; VIII_{AHF}, procoagulant activity of factor VIII; VIII_{vWF}, von Willebrand factor VIII activity.

Received for publication 20 December 1976 and in revised form 16 March 1977.
(3, 11, 12). Finally, the two biologic activities of normal factor VIII can be dissociated under conditions of high ionic strength, the activity of VIII_AHF appearing with those of lower molecular weight proteins, while that of VII_ⅧWF retains its high molecular weight characteristics (4, 6, 13–18). In this study, we present evidence that in all the above circumstances, the activity of VIII_AHF is relatively more labile and can be stabilized by the addition of the von Willebrand factor, or by hemophilic plasma which contains von Willebrand factor activity. By contrast, no stabilization was obtained with plasma of patients with severe von Willebrand’s disease. This stabilizing effect of the von Willebrand factor may have implications regarding the pathogenesis of the latter disorder.

METHODS

Nomenclature and assay of the factor VIII complex

The biologic components of the factor VIII complex are referred to as the antihemophilic factor (AHF) and the von Willebrand factor (VWF) and their respective activities are designated as follows: VIII_AHF is the procoagulant activity of factor VIII that corrects the coagulation defect in hemophilia, as measured by a one-stage method using the kaolin-activated partial thromboplastin time (3) and a Sherwood Lancer Coagulizer (Sherwood Medical Industries, Inc., St. Louis, Mo.) to read the end point; VII_ⅧWF is the activity of factor VIII in plasma that is required for ristocetin-induced platelet aggregation, assayed by a washed platelet system described previously (3). Factor VIII antigen, or VIII_AGN, is the antigen present in human plasma recognized by an antibody to human factor VIII and quantified by radioimmunoassay (19). The minimal sensitivities of these assays of these three components of the factor VIII complex are 1, 3, and 0.3 U/100 ml, respectively.

Preparation and storage of plasma

Venous blood was collected with 1/10 vol of 3.2% sodium citrate in polypropylene tubes (Ivan Sorvall, Inc., Norwalk, Conn.) and centrifuged at 2,400 g and 4°C for 30 min. The platelet-poor plasma was removed and assayed for VIII_AHF activity against pooled normal plasma, as previously described (3). Aliquots were frozen at −70°C for subsequent determination of VIII_ⅧWF and VIII_AGN.

Buffers

One part of a stock solution of 0.25 M imidazole of varying pH value was mixed with either four parts of normal saline (0.05 M imidazole-saline), nine parts of saline (0.025 M imidazole-saline), or nine parts of distilled water (0.025 M imidazole).

Determination of VIII_AHF stability

The stability of VIII_AHF activity at 37°C was determined by incubating plasma, diluted 1:10 in 0.05 M imidazole-saline buffer for varying periods of time in polystyrene tubes (Falcon Plastics, Div. BioQuest, Oxnard, Calif.) and determining VIII_AHF values (without further dilution) on the incubated specimens. The dependence of VIII_AHF stability on pH was determined by making the initial dilutions in buffers of varying pH, incubating for 4 h, and determining the residual VIII_AHF activity. Time-dependent VIII_AHF stability was determined with imidazole-saline buffer of pH 7.1 as the initial diluent and incubating for 0, 1, 2, 4, and 6 h. (The pH of the plasma-buffer mixtures did not differ by more than 0.04 pH U from that of the buffer alone.) The VIII_AHF activity in the incubated specimen was assayed and then expressed as a percentage of the initial (zero time) activity. In several studies, the buffer that was used to dilute the plasma contained 0.1% sodium azide in order to eliminate the possibility that the lability of VIII_AHF might be the result of bacterial growth and proteolysis during the incubation period.

Cryoprecipitability of VIII_AHF

In preliminary studies on normal plasma, we found the following method yielded the maximum amount of VIII_AHF in the cryoprecipitate and the maximum total recovery (cryoprecipitate plus supernate). A 12 × 75-mm polypropylene tube (Falcon Plastics) containing 2 ml of fresh plasma was placed in a −70°C freezer and kept there for at least 18 h. (Storage for up to 10 days did not affect the results.) The tube containing the frozen plasma was immersed in an ice bath and kept in a refrigerator for 3 h, after which time it was centrifuged at 2,400 g and 4°C for 15 min. The supernate was removed and the cryoprecipitate was dissolved in a total volume of 2 ml of 0.05 M imidazole-saline buffer, pH 7.1 at 37°C. Both supernate and cryoprecipitate were then diluted 1.5 and assayed for VIII_AHF. In all normal subjects, the ratio of VIII_AHF activity in cryoprecipitate to that in the supernate was 3.7±1.4 (SD). Recovery of the initial plasma VIII_AHF activity in the cryoprecipitate and supernate was 90±15%.

Preparation of purified von Willebrand factor devoid of VIII_AHF activity

A commercially available, semipurified factor VIII preparation material (Hemofil Method Four, Hyland Div., Trenoval Laboratories, Inc., Costa Mesa, Calif.) was dissolved in 0.025 M imidazole buffer, pH 7.1 containing 0.25 M CaCl2. The VIII_AHF activity, determined by assaying a 1:80 dilution of the dissolved factor VIII, was 36 U/ml. After incubation at room temperature for 30 min, 3.8 ml (137 U VIII_AHF) were applied to a siliconized column, 1.6 × 28 cm, of 4% agarose (Bio-Gel A-15m, Bio-Rad Laboratories, Richmond, Calif.) and eluted with imidazole buffer containing 0.25 M CaCl2 at 100 mm H2O outlet pressure and a flow rate of 0.15 ml/min. Under these conditions of high calcium concentration (13, 18, 20), 57% of the applied VIII_AHF was recovered from the column; 2% of the recovered activity appeared in the void volume, while the remaining activity eluted with proteins of lower molecular weight. The void volume fractions were rechromatographed on a 1.6 × 27-cm column containing Bio-Gel A-15m packed in 0.025 M imidazole buffer, but lacking CaCl2. Elution was carried out with imidazole-saline and the first fraction that showed ODmax (Buehler Fructoscan, Buehler Instruments Div., Scarle Analytic Inc., Fort Lee, N.J.) activity was removed and used in stabilization studies to be described. This fraction was devoid of any VIII_AHF activity but contained von Willebrand activity (see Table I). A lyophilized sample was dissolved in 0.01 M sodium phosphate buffer, pH 7.0, containing 1%
TABLE I

Characteristics of Posttransfusion Plasmas of a Patient with "Severe" von Willebrand's Disease

<table>
<thead>
<tr>
<th>Study</th>
<th>Time</th>
<th>Addition plasma (in vitro)</th>
<th>Factor VIII complex</th>
<th>Cryoprecipitation of VIII&lt;sub&gt;AHF&lt;/sub&gt;*</th>
<th>Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>h</td>
<td>U/100 ml</td>
</tr>
<tr>
<td>I‡</td>
<td>pre</td>
<td>—</td>
<td>—</td>
<td>&lt;1</td>
<td>&lt;3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>48</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>48</td>
<td>buffer</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>48</td>
<td>VWF</td>
</tr>
<tr>
<td>II§</td>
<td>pre</td>
<td>—</td>
<td>—</td>
<td>&lt;1</td>
<td>&lt;3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5</td>
<td>175</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>30</td>
<td>140</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>54</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>78</td>
<td>95</td>
</tr>
</tbody>
</table>

1U of cryoprecipitate is that obtained from 1 U (500 ml) of blood.

* Ratio of VIII<sub>AHF</sub> in cryoprecipitate (cryo) to that in supernate (supt) and percentage of initial plasma activity recovered (in cryo + supt).

‡ In transfusion study I, patient (V.M.) received 12 U of normal cryoprecipitate. The 48-h posttransfusion specimen was also studied after addition of purified von Willebrand factor (VWF) or buffer.

§ In transfusion study II, the patient received 113 U of cryoprecipitate over a 6-day period. Specimens were obtained at various intervals after the last transfusion.

sodium dodecyl sulfate (SDS). Reduction was carried out in 1.0% β-mercaptoethanol at 56°C for 2 h. Electrophoresis of the unreduced sample in a 5% acrylamide gel (bisacylamide/total acrylamide = 0.027) containing 0.1% SDS at 8 mA per tube for 4 h failed to disclose the presence of any protein (detectable by Coomassie Blue staining) that entered the gel (Fig. 1 A). Electrophoresis of the reduced sample disclosed the presence of a single faintly stained protein that entered the gel (Fig. 1 B) and had an apparent molecular weight (21) of about 225,000, estimated by comparison with the following markers (Sigma Chemical Co., St. Louis, Mo.): ribonuclease (mol wt 13,700), chymotrypsinogen (mol wt 25,700), egg albumin (mol wt 43,000), serum albumin (mol wt 68,000), and cold insoluble globulin (mol wt 420,000 unreduced and 210,000 reduced, kindly supplied by Dr. Michael Mosesson, Downstate Medical Center, State University of New York, Brooklyn, N. Y.). The estimated molecular weight of the von Willebrand factor is similar to previously reported values for factor VIII (22–27).

Preparation of low molecular weight factor VIII containing VIII<sub>AHF</sub> but no VIII<sub>VWF</sub> activity

Hemofil (250 mg) was dissolved in 3.5 ml of 0.025 M imidazole-saline, pH 7.2 containing soy bean trypsin inhibitor (STI, 0.1 mg/ml) and 10⁻³ M benzamidine HCL and chromatographed on a 2.6 x 40-cm column packed with Bio-Gel A-15m to a height of 28.5 cm. Elution was performed with imidazole-saline buffer containing STI and benzamidine at the above concentrations at a flow rate of 0.45 ml/min; fractions (4.1 ml) were collected by a drop counter. The eluate was continuously monitored for OD<sub>280</sub> and the first fraction containing detectable protein was removed. After the addition of anhydrous CaCl₂ to a final concentration of 0.25 M, the fraction was incubated for 30 min at room temperature, and then applied to a column (as above) packed with Bio-Gel A-15m. The buffer used to equilibrate and elute the column contained STI, benzamidine, and CaCl₂ (in the above concentrations). Fractions in which VIII<sub>AHF</sub> activity was anticipated (from previous studies) were pooled, applied to small columns packed with Sephadex G-75, and eluted with 0.025 M imidazole-saline. Aliquots of 2 ml were collected and assayed for VIII<sub>AHF</sub>; the fractions showing VIII<sub>AHF</sub> activity were pooled and used as the source of low molecular weight factor VIII. VIII<sub>VWF</sub> activity was undetectable in these fractions.

Chromatography of plasma on Bio-Gel A-15m

8 ml of plasma were applied through a flow adapter to the top of a 2.6 x 40-cm siliconized glass column packed to a height of 28.5 cm with Bio-Gel A-15m that had been previously equilibrated with 0.025 M imidazole-saline, pH 7.1,
containing 0.1% bovine albumin (Sigma Chemical). A flow rate of 0.7 ml/min was maintained by means of a Marriote flask using an outlet pressure of 100 cm H₂O. The amount of VIIIAHF in each fraction was determined from a standard curve constructed by diluting control plasma in imidazole-saline buffer containing 0.1% bovine albumin, and the activity in each fraction was expressed as a percent of the total recovered VIIIAHF activity. The elution pattern of VIIIAHF was characterized by calculating the VIIIAHF activity recovered in three summed fractions: I was the total activity in fractions 11–14, the first four fractions in which OD₃₄₀ was detectable; II was the activity in fractions 15–18; III was the activity in fractions 19–22. In seven normal plasmas, the percents of the total VIIIAHF activity recovered in pools I, II, and III were 84.1±6 (SD), 8.36±1.3, and 3.57±1.14%, respectively.

Mobility of factor VIII-related antigen on crossed immunoelectrophoresis

This was carried out in 0.9% agarose (Indubiose A37) using 5 × 7.5-cm glass slides. The buffer used for the preparation of the agarose and in the reservoirs was 0.025 M barbital, pH 9.5. Approximately 1 μl of Evan’s blue dye was added to 30 μl of plasma in a 5-mm well before electrophoresis at 8 V/cm (46 mA) for 1 h in a water-cooled electrophoresis chamber. The migration of Evan’s blue dye bound to albumin was measured (3.75–4.00 cm) before the agarose was removed from the top three-quarters of the slide and replaced by 4 ml of 0.9% of agarose containing a 1:500 dilution of rabbit anti-factor VIII-related antigen (19). Electrophoresis of the proteins into the agarose containing antibody was carried out at a constant current (1.8 mA/cm) for 20 h in the water-cooled chamber. The plate was then rinsed briefly in 0.5 M NaCl, 0.05 M phosphate, pH 7.2, and in distilled water before drying and staining with Coomassie Blue (28). VIIIAHF mobilities of plasmas are expressed as a ratio of the migration distance of the peak of the immunoprecipitate from the origin divided by the migration distance of albumin in that plasma. In order to concentrate plasmas with very low content of factor VIII-related antigen, an equal volume of 20% ethylene glycol 6,000 (J. T. Baker Chemical Co., Phillipsburg, N.J.) was first added. After continuous mixing for 1 h at 4°C, the precipitate was separated by centrifugation at 3,000 g for 20 min at 4°C. The precipitated proteins were dissolved in the barbital buffer (1/10 of the original plasma volume was added; the concentration of antigen in the dissolved precipitate was five times that of the starting plasma). In studies on five normal subjects, the average crossed immunoelectrophoresis mobility of factor VIII antigen in frozen plasma was found to be 97% (range 84–113%) of that in polyethylene glycol concentrate obtained from that plasma.

Plasmas used in study

Transfusion studies. A 31-yr-old female patient (V.M.) with severe von Willebrand’s disease (bleeding time >60 min) was transfused on three separate occasions. On the first occasion, she received 12 U of cryoprecipitate because of bleeding into her left knee, right elbow and right ankle, and a recurrence of gingival bleeding (transfusion I). 9 mo later, she received 113 U of cryoprecipitate over a 6-day period as treatment for gastrointestinal bleeding from an undisclosed site (transfusion II). Plasmas for study were obtained at various intervals after the last dose of cryoprecipitate. Values of the factor VIII complex in these plasmas are shown in Table I and are discussed further in Results. 2 mo after transfusion II, she was given 167 U of cryoprecipitate (transfusion III) over a 7-day period because of another episode of gastrointestinal bleeding. Values of the factor VIII complex in the posttransfusion plasma, as well as the results of other studies that are discussed later (see Results), are shown in Table II.

Patients with “mild” von Willebrand’s disease. Seven patients with the typical findings of a prolonged bleeding time and decreased levels of the factor VIII complex (Table III) were studied. Levels of VIIIAHF activity in these patients ranged from 30–50 U/100 ml, levels of VIIIAHF were 6–46 U/100 ml, and those of VIIAGN were 2–43 U/100 ml.

---

**TABLE II**

VIIIAHF-Elution Pattern and Factor VIII Antigen Mobility of (VIIIAHF-Labile) Posttransfusion Plasmas

| Time after transfusion | Factor VIII complex | VIIIAHF stability in vitro, initial activity | VIIIAHF activity recovered in chromatographic fractions | Elution pattern, recovered activity* | Relative mobility of VIIIAHF
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>h U/100 ml</td>
<td>AHF VWF AGN</td>
<td>%</td>
<td>%</td>
<td>I II III R</td>
<td></td>
</tr>
<tr>
<td>Patient V.M. (study III)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>160 86 83</td>
<td>61</td>
<td>79</td>
<td>72 17 7 4</td>
<td>0.33</td>
</tr>
<tr>
<td>24</td>
<td>97 60 74</td>
<td>62</td>
<td>—</td>
<td>— — — —</td>
<td>0.37</td>
</tr>
<tr>
<td>48</td>
<td>85 38 45</td>
<td>59</td>
<td>—</td>
<td>— — — —</td>
<td>0.41</td>
</tr>
<tr>
<td>72</td>
<td>82 16 22</td>
<td>37</td>
<td>69</td>
<td>62 22 8 8</td>
<td>—</td>
</tr>
<tr>
<td>79</td>
<td>73 6 20</td>
<td>38</td>
<td>—</td>
<td>— — — —</td>
<td>—</td>
</tr>
<tr>
<td>96</td>
<td>50 4 12</td>
<td>39</td>
<td>52</td>
<td>53 26 18 3</td>
<td>—</td>
</tr>
<tr>
<td>Normal subjects (n = 20)†</td>
<td>(n = 11)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mean</td>
<td>92 95 103</td>
<td>77</td>
<td>72</td>
<td>84 8 4 4</td>
<td>0.32</td>
</tr>
<tr>
<td>SD</td>
<td>18 20 29</td>
<td>12</td>
<td>17</td>
<td>3 1 1 2</td>
<td>0.015</td>
</tr>
</tbody>
</table>

* VIIIAHF in fractions 11–14 (I), 15–18 (II), 19–22 (III), and the remainder (R) of the fractions eluted after chromatography of plasma on Bio-gel A-15m, expressed as percent of the recovered activity.
† Data from previous study (3).

Stabilization of Factor VIII by the von Willebrand Factor
**TABLE III**

Characteristics of Plasmas in Patients with "Mild" von Willebrand's Disease

<table>
<thead>
<tr>
<th>Source</th>
<th>Factor VIII complex</th>
<th>VIII&lt;sub&gt;AHF&lt;/sub&gt; activity recovered in chromatographic fractions</th>
<th>Elution pattern, recovered activity&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Relative mobility of VIII&lt;sub&gt;AGN&lt;/sub&gt;</th>
<th>Cryoprecipitability of VIII&lt;sub&gt;AHF&lt;/sub&gt;*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>U/100 ml</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>von Willebrand's</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Z.D.</td>
<td>33</td>
<td>26</td>
<td>27</td>
<td>48</td>
<td>82</td>
</tr>
<tr>
<td>E.D.</td>
<td>50</td>
<td>36</td>
<td>30</td>
<td>77</td>
<td>82</td>
</tr>
<tr>
<td>S.B.</td>
<td>45</td>
<td>40</td>
<td>30</td>
<td>69</td>
<td>77</td>
</tr>
<tr>
<td>W.G.</td>
<td>40</td>
<td>46</td>
<td>43</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>J.M.</td>
<td>35</td>
<td>8</td>
<td>5</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>J.L.</td>
<td>33</td>
<td>7</td>
<td>15</td>
<td>66</td>
<td>56</td>
</tr>
<tr>
<td>A.S.</td>
<td>30</td>
<td>6</td>
<td>2</td>
<td>46</td>
<td>71</td>
</tr>
<tr>
<td>Normal subjects</td>
<td>(n = 20)§</td>
<td></td>
<td>(n = 7)</td>
<td>(n = 6)</td>
<td>(n = 11)</td>
</tr>
<tr>
<td>mean</td>
<td>92</td>
<td>95</td>
<td>103</td>
<td>72</td>
<td>84</td>
</tr>
<tr>
<td>SD</td>
<td>18</td>
<td>29</td>
<td>29</td>
<td>17</td>
<td>3</td>
</tr>
</tbody>
</table>

* Ratio of VIII<sub>AHF</sub> in cryoprecipitate (cryo) to that in supernate (supt) and percentage of initial plasma activity recovered (in cryo + supt).
† VIII<sub>AHF</sub> in fractions 11–14 (I), 15–18 (II), 19–22 (III), and the remainder (R) of the fractions eluted after chromatography of plasma ion Bio-gel A-15m, expressed as percent of the recovered activity.
§ Data from previous study (3).

**Normal subjects.** Plasmas from healthy hospital employees were used as controls.

**Other plasmas used in study**

Plasmas of four patients with severe hemophilia (VIII<sub>AHF</sub> deficiency) were used as a source of von Willebrand factor in some studies. As controls for these studies, we used plasmas from three patients with severe von Willebrand's disease. The values of the factor VIII complex in these seven patients are shown in Table IV.

**RESULTS**

**Stability of VIII<sub>AHF</sub> in normal plasmas.** In preliminary studies, incubation of plasma from 16 normal subjects for 4 h in buffers of varying pH values showed that VIII<sub>AHF</sub> activity was best maintained in the pH range of 6.9–7.25 (Fig. 2 A), similar to findings in previous studies (29, 30). For determining sequential loss of VIII<sub>AHF</sub> activity in plasma during incubation at 37°C, we elected to use a buffer of pH 7.1. The sequential loss of activity in normal plasma during 6 h of incubation at this pH value is shown in Fig. 2 B and shows that 77 ± 12% (SD) of the initial activity remained in the plasma after 6 h of incubation.

**Increased lability of VIII<sub>AHF</sub> in late posttransfusion plasmas, corrected by von Willebrand factor.** The levels of the factor VIII complex in the plasma of patient V.M. at varying intervals after transfusion of cryoprecipitate on two separate occasions (studies I and II) are shown in Table I. They demonstrate the type of dissociation reported in previous studies: the VIII<sub>AHF</sub> levels remained increased, while those for VIII<sub>VWF</sub> and VIII<sub>AGN</sub> were declining. In transfusion study I, the levels of VIII<sub>AHF</sub> in the 1-h and 48-h posttransfusion samples were almost identical (29 and 28 U/100 ml, respectively). However, VIII<sub>VWF</sub> and VIII<sub>AGN</sub> levels in the 1-h posttransfusion plasma were 39 and 27 U/100 ml, whereas the levels in the 48-h plasma were <3 and 3 U/100 ml, respectively, for these factors. The stability of VIII<sub>AHF</sub> activity in these two plasmas were studied on aliquots that had been frozen at −70°C for 5–10 days. (VIII<sub>AHF</sub> values on these stored plasma specimens were

**TABLE IV**

Plasmas Used in Correction Studies

<table>
<thead>
<tr>
<th>Source</th>
<th>Factor VIII complex</th>
<th>U/100 ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>C.M. □</td>
<td>2</td>
<td>&lt;3</td>
</tr>
<tr>
<td>D.R. △</td>
<td>2</td>
<td>&lt;3</td>
</tr>
<tr>
<td>V.M. ○</td>
<td>&lt;1</td>
<td>&lt;3</td>
</tr>
<tr>
<td>Hemophilia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J.R. ▼</td>
<td>&lt;1</td>
<td>128</td>
</tr>
<tr>
<td>M.R.* ●</td>
<td>&lt;1</td>
<td>95</td>
</tr>
<tr>
<td>P.R.* ▲</td>
<td>&lt;1</td>
<td>112</td>
</tr>
<tr>
<td>M.B. ▼</td>
<td>&lt;1</td>
<td>165</td>
</tr>
</tbody>
</table>

Symbols are those depicted for the plasmas of these patients used in experiments shown in Figs. 4, 8, 9, and 10.

* P.R. and M.R. are brothers, unrelated to J.R. and M.B.
virtually identical to those obtained on the fresh specimens before freezing.) Incubation of these plasmas (diluted with 1:10 in imidazole-saline, pH 7.1) for 6 h (Fig. 3 A) showed that VIII_AHF activity in the 48-h (von Willebrand factor-poor) plasma was strikingly labile, whereas the activity in the 1-h (von Willebrand factor-rich) plasma was similar to that of normal plasma. The results were entirely similar with the plasmas obtained after transfusion study II. In this study, a progressive dissociation of the values of the factor VIII complex also occurred (Table I); for example, 78 h after the transfusion, the VIII_AHF level was 95 U/100 ml, while that of VIII_vWF and VIII_AHF was 36 and 28 U/100 ml, respectively. As in study I, the VIII_AHF activity was more labile in the late (e.g., 30, 54, and 78 h) posttransfusion plasmas that were (relative to VIII_AHF) von Willebrand-poor than the 5-h plasma (Fig. 3 B). In the latter plasma, the stability of VIII_AHF activity was normal.

The VIII_AHF activity in the 48-h posttransfusion I plasma could be stabilized by the prior addition of purified von Willebrand factor (Fig. 4 A), which increased the VIII_vWF and VIII_ANG levels to 51 and 69 U/100 ml, without any detectable effect on the VIII_AHF level (Table I and Fig. 4 A). Plasmas from hemophilic patients (which contain the von Willebrand factor; Table IV) also stabilized VIII_AHF activity in the 48-h posttransfusion I plasma, whereas plasmas from three patients with severe von Willebrand’s disease (Table IV) were without effect (Fig. 4 B).

The above studies indicate that the activity of VIII_AHF in posttransfusion plasmas that are relatively deficient in VIII_vWF and/or VIII_ANG is labile and can be stabilized either by purified von Willebrand factor or by plasmas that contain VIII_vWF activity, but not by plasmas deficient in this activity. The increased lability at pH 7.1 of VIII_AHF posttransfusion plasmas is not the result of a change in the optimum pH for maintaining VIII_AHF activity, as demonstrated by the pH-stability curves shown in Fig. 5.

**Aberrant nature of factor VIII in posttransfusion plasmas.** The results of transfusion III (Table II) suggest that the labile nature of VIII_AHF and VIII_vWF is due to dissociation of the VIII complex, particularly factor VIII_vWF, in the posttransfusion period. This dissociation is exacerbated by the addition of acidic pH to the plasmas, which decreases the stability of factor VIII_vWF, as observed in the pH-stability curves shown in Fig. 5.
showed that, in addition to being more labile, the VIIIₐHₐF activity in late posttransfusion plasma also eluted differently from Bio-Gel A-15m than that in normal or early posttransfusion plasma. As seen in Table II and Fig. 6, 84±3% (SD) of the recovered VIIIₐHₐF activity from normal plasma eluted in the void volume. In plasma obtained 30, 72, and 96 h after transfusion, the void volume VIIIₐHₐF was 72, 62, and 53%, respectively, of its total recovered activity. Note, however, that although a greater percentage of the VIIIₐHₐF activity in the late posttransfusion samples eluted after the void volume, no sharp peak of lower molecular weight activity was observed. In addition, when these post-void volume fractions were pooled, concentrated in cellophane membranes (Spectrapor, Fisher Scientific Co., Pittsburgh, Pa.) against polyethylene glycol flakes (mol wt 20,000), and chromatographed on Bio-Gel A-15m in the presence of 0.002 M CaCl₂, which prevents re-aggregation of low molecular weight factor VIII (31), the VIIIₐHₐF activity continued to elute after the void volume, but again, no sharp peak was observed. Measurements of the mobility of factor VIII antigen in 3-, 24-, and 48-h posttransfusion plasmas showed a progressive increase in mobility (Table II and Fig. 7). Mobilities in the 72-, 79-, and 96-h specimens would have required concentration of the plasmas, which was precluded by the limited volume of the samples available.

Increased lability of VIIIₐHₐF activity in patients with von Willebrand’s disease who have “aberrant” von Willebrand factor. The stability of plasma VIIIₐHₐF activity at pH 7.1 was studied in seven patients (Table III) with “mild” von Willebrand’s disease. Results are shown in Fig. 8. In four patients, stability of VIIIₐHₐF was either normal or only slightly decreased (Fig. 8, open circles). In these four patients, the average ratio of VIIIₐHₐF activity to that of VIIIᵥWF or VIIIₐGN was 1.2 and 1.3, respectively, and in no individual was this this ratio >1.6. The VIIIₐHₐF activity was strikingly more labile in the plasma of the three other patients (Fig. 8, closed circles), in whom the ratios of VIIIₐHₐF to VIIIᵥWF and/or VIIIₐGN were greater, averaging 4.7 and 8.1, respectively. In two of these patients (J.L. and A.S., the third patient, J.M., was not studied), the elution pattern of VIIIₐHₐF after chromatography of plasma on Bio-Gel A-15m was different than

![Figure 3](http://www.jci.org)
that obtained with normal plasma or other patients with von Willebrand's disease. In these two patients, a lesser percentage of the recovered VIII$_{AHF}$ activity was found in the void volume fractions (Table III). The remaining activity entered the gel, but, as was the case with the late posttransfusion plasmas, no distinct peak of low molecular weight activity was observed. In addition, the mobility of factor VIII antigen (studied by crossed immunoelectrophoresis) in these two patients was also more anodal than in normal subjects, or in other patients with von Willebrand's disease (Table III and Fig. 7). The above findings suggest that the von Willebrand factor/factor VIII-related protein may differ from normal in these patients with labile VIII$_{AHF}$ activity.

**Stabilization of VIII$_{AHF}$ activity in “aberrant” von Willebrand’s disease by the von Willebrand factor.**

As was true of the late posttransfusion plasmas of patient V.M., the VIII$_{AHF}$ activity in the plasma of patient A.S. could be stabilized by the addition of purified von Willebrand factor (Fig. 9 A) and by plasmas of patients with hemophilia (Fig. 9 B). In contrast, plasmas of patients with severe von Willebrand's disease were without effect (Fig. 9 B). Entirely similar results were obtained with plasmas of the other two patients (J.L. and J.M.) with aberrant von Willebrand factor (Fig. 10). In separate studies in which normal plasma was mixed with equal volumes of either buffer, hemophilic plasma, or plasma of a patient with severe von Willebrand's disease, we found that von Willebrand plasma did not “destabilize” the VIII$_{AHF}$ activity of normal plasma (data not shown).

**Stability of VIII$_{AHF}$ activity in dissociated, low molecular weight factor VIII.** Low molecular weight factor VIII, containing VIII$_{AHF}$ activity, but no detectable VIII$_{vWF}$ activity, was incubated with plasmas of patients with hemophilia or von Willebrand's disease. Results are shown in Fig. 11. The VIII$_{AHF}$ activity appeared to be more stable than that in native, normal plasma; therefore, longer incubation periods (24-48 h) were required to demonstrate significant loss of activity. Nevertheless, even with these modified conditions of incubation, the VIII$_{AHF}$ activity of “low molecular weight factor VIII” was considerably more
stable in hemophilic plasma than in the plasma of patients with von Willebrand's disease (Fig. 11).

Cryoprecipitability of VIII_AHF activity. As shown in Table II, the ratio of VIII_AHF in the cryoprecipitate to that in the supernate (C/S) was 3.7±1.3 (SD) in normal subjects. In four patients with von Willebrand's disease, the C/S ratio was within the mean ±2 SD values of normal subjects. The cryoprecipitability of VIII_AHF was low in the three patients with "labile" VIII_AHF and low VIIIR:VIII_AGN values. In patient J. L., cryoprecipitability was only moderately reduced (C/S = 1.0), whereas strikingly low values (0.3 and 0.1) were obtained in patients J. M. and A. S. When the plasma of patient A. S. was mixed with equal parts of hemophilic plasmas before freezing, the C/S ratio increased to 0.5 (mean of three different plasmas), whereas it remained 0.1 when mixed with plasmas of patients with von Willebrand's disease. Decreased cryoprecipitability was also found in the late posttransfusion plasmas (patient V. M.) that were relatively deficient in VIIIR:VWF activity (Table I). Addition of von Willebrand factor to the 48-h posttransfusion plasmas of study I increased the cryoprecipitability of VIII_AHF from 0.4 to 1.1.

Attempts to stabilize VIII_AHF activity in normal plasma. The addition of the following substances to normal plasma did not stabilize the VIII_AHF activity during 6 h of incubation: heparin (0.025 and 0.05 U/ml), Trasylol (100 U/ml), e-amino caproic acid 0.05 M, STI (10^{-4} M), or benzamidine HCl (10^{-4} M). The presence of sodium azide in the diluting buffer did not increase the stability of VIII_AHF in either normal plasma, the plasma of patient A. S., or late posttransfusion plasmas showing increased VIII_AHF lability.

DISCUSSION

The structure-function relationships of factor VIII that determine the plasma levels of VIII_AHF, VIIIR:VWF, and VIII_AGN are not clear. It is generally agreed that VIII_AGN is a property of a $1.2 \times 10^6$ dalton molecule that is composed of 200,000 mol wt subunits and possesses VIIIR:VWF activity as well (2, 32). Thus, impaired association of abnormally charged subunits (9, 10, 33, 34)

---

**FIGURE 5** pH-Stability curves on posttransfusion plasmas. Plasmas (study I, Table I) were diluted 1:10 with imidazole-saline (pH 7.1) of varying pH values and incubated at 37°C for 4 h. Depicted are the curves obtained for the 1-h plasma (x), the 48-h plasma (o), and the 48-h plasma to which purified von Willebrand factor had been added (●). The curve obtained with normal plasmas (Fig. 2A) is shown by the dashed line (---).

H. J. Weiss, I. I. Sussman, and L. W. Hoyer
FIGURE 6  Chromatography of normal and posttransfusion plasmas on Bio-Gel A-15m. 8 ml of plasma was chromatographed on Bio-Gel A-15m (2.6 x 28.5 cm). In normal plasma, 84±3% (SD) of the recovered VIII_AHF is eluted as a sharp peak in the void volume (see Table II). In the late (72 and 96 h) posttransfusion (Tx) III plasmas of patient V. M., a relatively lesser percent of the recovered activity was found in the void volume (see also Table II), but there was no sharp peak of activity eluting after the void volume.

FIGURE 7  Crossed immunoelectrophoresis pattern of factor VIII-related antigen. (A) Normal plasma. The anode in the first electrophoretic separation is to the right; that for the second separation is at the top of the figure. (B) Concentrated plasma from patient A. S. Although the peak height is less, the major fraction of this protein has a faster mobility than the peak value for normal plasma. This separation is typical of four such electrophoretic separations. (C) Plasma obtained from patient V. M. 3 h after the last transfusion of cryoprecipitate (transfusion III). (D) 48 h posttransfusion III. Most of the factor VIII protein has a faster mobility than that obtained 3 h after transfusion.
molecules on which VIII_AHF is active (24–26). However, dissociation of factor VIII into smaller subunits with VIII_AHF activity has also been achieved with sucrose density ultracentrifugation (37, 38), a method in which adsorption cannot play a role. A second theory holds that VIII_AHF activity is the property of a molecule that is distinct from that responsible for VIII_VWF but whose plasma level is somehow determined by it (39, 40), or is noncovalently bound to VIII_VWF (carrier hypothesis) (41, 42). The evidence supporting both the one- and two-molecule theories has been summarized recently (2, 43), and it is clear that the problem will not be solved until “low molecular weight” VIII_AHF—free of the protein carrying VIII_AGN/VIII_VWF—is obtained in sufficient quantity for analysis so that its structure can be compared with that of VIII_VWF/VIII_AGN (2).

The uncertainties about the molecular structure of the factor VIII complex make it difficult to know the basis for dissociation of VIII_AHF from VIII_VWF/VIII_AGN observed in the plasmas of some patients with von Willebrand’s disease, as well as in the posttransfusion plasmas of other patients. Earlier studies by Barrow et al. (44) suggested that posttransfusion VIII_AHF was indistinguishable from normal VIII_AHF, as judged by its inactivation at 50°C and pH-dependent stability. Subsequently, however, other investigators have reported that the VIII_AHF activity in posttransfusion plasmas of both humans (6, 45) and pigs (46) with von Willebrand’s disease appears to lose its activity more rapidly than that in normal plasmas when stored at –20°C. The results obtained in the present study confirm and extend these latter findings by demonstrating that the VIII_AHF is relatively more labile in late posttransfusion plasmas, in which VIII_AHF > VIII_VWF activity, but that the stability of VIII_AHF in early posttransfusion plasma (VIII_AHF ~ VIII_VWF) is the same as in normal plasma. Furthermore, VIII_AHF in late posttransfusion plasmas show diminished cryoprecipitability. Both the increased lability of VIII_AHF and the decreased cryoprecipitability appear to be related to the increased VIII_AHF to VIII_VWF ratio in late posttransfusion plasmas; both abnormalities can be corrected by the addition of a purified plasma fraction that contains VIII_VWF but is lacking in VIII_AHF activity. Plasmas from hemophilic patients (which contain VIII_VWF) also stabilized VIII_AHF activity, whereas those from patients with severe von Willebrand’s disease did not. Thus, VIII_VWF appears to stabilize VIII_AHF specifically.

It is of interest to consider the possible relationship of these findings to the “over-response” of VIII_AHF observed after transfusion in von Willebrand’s disease. An important missing piece of information, however, is whether the increased lability of VIII_AHF in vitro is equally true in vivo. We have no evidence on this point. Previous studies suggested that the loss of
activity of VIII\textsubscript{AHF} in normal plasma during incubation at 37°C is enzymatic in nature (29, 47). In neither of these studies, nor in the present study, was an enzymatic process identified, although it is of some interest that Kekwick and Walton (48) have described the presence of a diisopropylfluorophosphate-sensitive inhibitor of VIII\textsubscript{AHF} in factor VIII concentrates. If the in vitro findings in the present study are true in vivo, it is possible that the von Willebrand factor may serve to stabilize VIII\textsubscript{AHF} in vivo (and possibly promote its release from its site of synthesis), thereby increasing the levels of VIII\textsubscript{AHF} activity in plasma. The basis for the posttransfusion response in von Willebrand’s disease would thus represent the presence in plasma of VIII\textsubscript{AHF}, synthesized under the control of normal X chromosomes, which is stabilized by the presence of added “normal” VIII\textsubscript{AGN}/VIII\textsubscript{VWF} protein. The different ratios of VIII\textsubscript{AHF} to VIII\textsubscript{VWF}/VIII\textsubscript{AGN}—compared to the normal plasma standard—in these situations cannot be interpreted on a molecular basis at this time because the exact molecular weights, concentrations, and combining ratios of these properties are not known absolutely but are only compared to those of a reference plasma.

At our present level of understanding, the stabilizing effect of VIII\textsubscript{VWF} on VIII\textsubscript{AHF} activity does not provide new information that allows choices between a one-molecule or two-molecule theory for factor VIII. For example, the VIII\textsubscript{VWF} might inhibit the activity of a plasma protease that inactivates VIII\textsubscript{AHF} (two separate molecule theory). Alternatively, it might, as a carrier, bind VIII\textsubscript{AHF} and thereby prevent its inactivation. This theory has been proposed by Bloom et al. (41) who reported that some of the posttransfusion VIII\textsubscript{AHF} eluted from agarose gels in a sharp peak after the void volume, suggesting that this represented unbound VIII\textsubscript{AHF}. This finding was not confirmed in our experiments nor in those of Muntz et al. (6). Although we did find that a relatively greater percent of the recovered VIII\textsubscript{AHF} eluted after the void volume (Table II), no sharp peak was discernible (Fig. 6). An alternative explanation, based on the one-molecule hypothesis, might be that factor VIII, with active procoagulant activity (VIII\textsubscript{AHF}), is specifically synthesized and released after transfusion, but that this is relatively labile in vitro and can be converted to an inactive form. Thus, addition of the von Willebrand factor (either purified from normal plasma or present in

**Stabilization of Factor VIII by the von Willebrand Factor**

401
PLASMA ADDED

HEMOPHILIA

VON WILLEBRAND'S

BUFFER

PLASMA ADDED

HEMOPHILIA

VON WILLEBRAND'S

BUFFER

Fig. 10 Stabilization of VIIA_HF activity in the plasmas of patients J. L. and J. M. by hemophilic plasma. 0.2 ml of plasma of patient J. L. (A) or J. M. (B) were mixed with 0.2 ml of plasma from patients with either hemophilia (closed figures) or von Willebrand's disease (open figures; see Table III), or with buffer (x -- - - x). The mixtures were diluted with 3.6 ml of imidazole-saline, pH 7.1, and incubated at 37°C. For patient J. M., lines connect mean values (bars).

Fig. 11 VIIA_HF stability of dissociated, low molecular weight factor VIII in hemophilic and von Willebrand plasma. 0.4 ml of dissociated factor VIII (see Methods) was mixed with an equal volume of plasma from patients with hemophilia (closed figures) or with von Willebrand's disease (open figures; see Table III). The mixture was diluted with 3.2 ml of 0.05 M imidazole-saline, pH 7.2, and incubated at 37°C. Initial VIIA_HF activity was 12 U/100 ml.

The findings obtained in posttransfusion plasmas are similar to those in the three patients with von Willebrand's disease who showed the dissociation phenomena, i.e., VIIA_HF values > VIIA_VWF. VIIA_HF in these plasmas was also labile, whereas this was not the case in four other patients in whom VIIA_HF levels were similar to those for VIIA_VWF. As in the late posttransfusion plasmas, the increased lability of VIIA_HF in the plasmas of these patients could also be corrected by von Willebrand factor or hemophilic plasmas that contained VIIA_VWF, but not by plasmas of patients with von Willebrand's disease. Furthermore, the increased mobility of VIIA_GN on crossed immunoelectro-
phoresis in two of these patients, as well as decreased cryoprecipitability of \( \text{VIII}_{\text{AHF}} \), and the delayed elution pattern of \( \text{VIII}_{\text{AHF}} \) after agarose gel chromatography, demonstrates properties of factor VIII in these patients that are similar to those of late posttransfusion plasma. These three observations may, in fact, represent consequences of a shift in factor VIII size in these situations. Zimmerman and his co-workers (35) have demonstrated that the faster-moving forms on crossed immunoelectrophoresis are probably due to reduced size, not increased charge, and this property is consistent with the slightly later elution patterns on agarose gel chromatography. The relationship of cryoprecipitability to large size has also been identified in these studies (35). Thus, our findings for these patients with von Willebrand variants and aberrant \( \text{VIII}_{\text{VF}} \) provide additional evidence that \( \text{VIII}_{\text{AHF}} \) is relatively labile in vitro in the absence of normal \( \text{VIII}_{\text{VF}} \). They emphasize that the abnormalities in \( \text{VIII}_{\text{VF}} \) structure and concentration are central to the factor VIII defect in von Willebrand’s disease.

ACKNOWLEDGMENTS
The authors wish to thank Mr. John Rogers for his expert technical assistance.
This work was supported in part by grants HL 14595, HL 16626, and HL 16872 from the National Heart, Lung, and Blood Institute.

REFERENCES